Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools GIST

GIST

Programs, trials, and reported response and survival for gastrointestinal stromal tumor.

Data as of 11.07.2026

All studies

Velzatinib (IDRX-42, GSK6042981)

StrateGIST 3

GSK · Phase 3 · Recruiting · Enrollment 450

NCT07218926

Catalyst Primary completion. 05.30.2028. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.

ArmPopulationDoseEstimandComparatorEfficacy
Velzatinib 300 mgGIST after imatinib; excludes KIT/PDGFRA wild type and PDGFRA exon 18300 mgITTsunitinib 50 mg 4/2n/r
Sunitinib 50 mg 4/2GIST after imatinib50 mgITTn/rn/r

No efficacy figure is in this file for this study.